Photo from wikipedia
A phase II trial of the MET inhibitor capmatinib found that 72% of treatment-naïve patients responded to the drug, whereas the response rate for previously treated patients was 39.1%. The… Click to show full abstract
A phase II trial of the MET inhibitor capmatinib found that 72% of treatment-naïve patients responded to the drug, whereas the response rate for previously treated patients was 39.1%. The drug's side effects include peripheral edema, nausea, and vomiting.
Keywords:
triggers responses;
capmatinib triggers;
responses nsclc;
capmatinib
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!